DK3078744T3 - Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne - Google Patents

Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne Download PDF

Info

Publication number
DK3078744T3
DK3078744T3 DK14867380.9T DK14867380T DK3078744T3 DK 3078744 T3 DK3078744 T3 DK 3078744T3 DK 14867380 T DK14867380 T DK 14867380T DK 3078744 T3 DK3078744 T3 DK 3078744T3
Authority
DK
Denmark
Prior art keywords
antigen binding
molecules
libraries
compounds
concentration
Prior art date
Application number
DK14867380.9T
Other languages
English (en)
Inventor
Tomoyuki Igawa
Shigero Tamba
Shun Shimizu
Kanako Tatsumi
Shojiro Kadono
Hiroki Kawauchi
Kazuhiro Ohara
Masayuki Matsushita
Takashi Emura
Masaki Kamimura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53273524&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3078744(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3078744T3 publication Critical patent/DK3078744T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • C40B50/16—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support involving encoding steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Structural Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK14867380.9T 2013-12-04 2014-12-04 Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne DK3078744T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013251537 2013-12-04
PCT/JP2014/082060 WO2015083764A1 (ja) 2013-12-04 2014-12-04 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ

Publications (1)

Publication Number Publication Date
DK3078744T3 true DK3078744T3 (da) 2020-09-28

Family

ID=53273524

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14867380.9T DK3078744T3 (da) 2013-12-04 2014-12-04 Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne

Country Status (14)

Country Link
US (3) US10961530B2 (da)
EP (2) EP3078744B1 (da)
JP (3) JP7060317B2 (da)
KR (3) KR102454360B1 (da)
CN (2) CN111304752A (da)
AU (1) AU2014358191B2 (da)
BR (1) BR112016012094A2 (da)
CA (1) CA2931296C (da)
DK (1) DK3078744T3 (da)
EA (1) EA201691154A1 (da)
MX (1) MX2016007312A (da)
SG (1) SG11201604495PA (da)
TW (3) TWI702316B (da)
WO (1) WO2015083764A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013268418B2 (en) 2012-05-30 2017-12-07 Chugai Seiyaku Kabushiki Kaisha Target-tissue-specific antigen-binding molecule
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP3004892B1 (en) * 2013-05-24 2018-10-10 Nestec S.A. Method for diagnosing irritable bowel syndrome
KR102291045B1 (ko) 2013-08-05 2021-08-19 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
WO2015083764A1 (ja) 2013-12-04 2015-06-11 中外製薬株式会社 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3307282A4 (en) * 2015-06-12 2019-05-01 Immunomedics, Inc. TREATMENT OF DISEASES WITH CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (T-CAR) OR NK (CAR-NK) CELL EXPRESSION CONSTRUCTIONS CAR CONSTRUCTIONS
US10844373B2 (en) 2015-09-18 2020-11-24 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
JP6920293B2 (ja) * 2015-10-30 2021-08-18 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ＩｇＧ軽鎖におけるＮ末端切断の防止
CN115920796A (zh) 2015-12-01 2023-04-07 特韦斯特生物科学公司 功能化表面及其制备
GB2568444A (en) 2016-08-22 2019-05-15 Twist Bioscience Corp De novo synthesized nucleic acid libraries
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CA3047128A1 (en) 2016-12-16 2018-06-21 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018140525A1 (en) * 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
WO2018170169A1 (en) * 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018189611A1 (en) * 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
JP2020536504A (ja) 2017-09-11 2020-12-17 ツイスト バイオサイエンス コーポレーション Ｇｐｃｒ結合タンパク質およびその合成
WO2019079769A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES
CN109988748A (zh) * 2017-12-29 2019-07-09 深圳华大生命科学研究院 一种从til筛选肿瘤特异性t细胞的方法
AU2019205269A1 (en) 2018-01-04 2020-07-30 Twist Bioscience Corporation DNA-based digital information storage
EP3753956A4 (en) * 2018-02-14 2021-12-22 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE AND COMBINATION
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
AU2019318031A1 (en) * 2018-08-10 2021-02-25 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109293778B (zh) * 2018-11-01 2021-09-17 浙江蓝盾药业有限公司 同时抗cd70和cd47的重链抗体及其制备方法和应用
EP3903816A4 (en) * 2018-12-28 2022-09-07 Kyowa Kirin Co., Ltd. TRANSFERRIN RECEPTOR (TFR) BISPECIFIC ANTIBODY
SG11202109283UA (en) 2019-02-26 2021-09-29 Twist Bioscience Corp Variant nucleic acid libraries for antibody optimization
CN113766930A (zh) 2019-02-26 2021-12-07 特韦斯特生物科学公司 Glp1受体的变异核酸文库
EP3943108A4 (en) * 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
EP3987019A4 (en) 2019-06-21 2023-04-19 Twist Bioscience Corporation BARCODE-BASED NUCLEIC ACID SEQUENCE ARRANGEMENT
BR112022011723A2 (pt) * 2019-12-27 2022-09-06 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4 e uso do mesmo
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
WO2023159140A2 (en) * 2022-02-17 2023-08-24 Adimab, Llc Anti-asgr1 polypeptides and methods of use for immune tolerance
CN115385990B (zh) * 2022-08-22 2023-06-02 首都医科大学附属北京妇产医院 分离的多肽及其在用于诊断或预测卵巢癌中的用途和检测设备

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997009068A2 (en) * 1995-09-01 1997-03-13 University Of Washington Interactive molecular conjugates
US20040241759A1 (en) * 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
JP5002105B2 (ja) 1999-12-28 2012-08-15 リボノミックス， インコーポレイテッド 内因性のｍＲＮＡタンパク質（ｍＲＮＰ）複合体の単離および特徴付けの方法
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60228721D1 (en) 2001-06-22 2008-10-16 Chugai Pharmaceutical Co Ltd Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
EP1511861A4 (en) 2002-06-12 2007-12-05 Genencor Int METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
JP2005292087A (ja) 2004-04-05 2005-10-20 Shionogi & Co Ltd ５’−デオキシ−５’−メチルチオアデノシンに対する抗体
WO2005115452A2 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
JP5143551B2 (ja) * 2004-07-06 2013-02-13 バイオレン，インク． ユニバーサル抗体のライブラリー
ATE486610T1 (de) 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
RU2412200C2 (ru) 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
SI2573114T1 (sl) 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP1954720A1 (en) 2005-10-31 2008-08-13 The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health Antibodies and immunotoxins that target human glycoprotein nmb
WO2007063539A1 (en) 2005-11-30 2007-06-07 Can-Fite Biopharma Ltd. Therapeutic uses of a3 adenosine receptor antibodies
NZ574473A (en) 2006-08-02 2013-02-22 Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CA2764852C (en) 2007-01-05 2018-09-18 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
DK2176298T3 (da) 2007-05-30 2018-02-12 Xencor Inc Fremgangsmåder og sammensætninger til inhibering af CD32B-udtrykkende celler
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
CA2699916A1 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
MX349306B (es) 2007-09-21 2017-07-19 Univ California Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales.
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
CA3086659A1 (en) 2007-12-26 2009-07-09 Xencor, Inc. Fc variants with altered binding to fcrn
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8541178B2 (en) 2008-05-13 2013-09-24 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
CA2736277C (en) 2008-09-10 2016-06-21 Philochem Ag Display library for antibody selection
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
US8647829B2 (en) 2009-02-20 2014-02-11 General Electric Company Switchable affinity binders
NO2406399T3 (da) 2009-03-09 2018-07-14
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
BRPI1012193A2 (pt) 2009-05-01 2019-09-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP2011097869A (ja) 2009-11-05 2011-05-19 Japan Science & Technology Agency 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
JP2011184418A (ja) * 2010-03-11 2011-09-22 Tokyo Institute Of Technology 親和性可変抗体
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
WO2012044831A1 (en) 2010-09-30 2012-04-05 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
DK2698431T3 (da) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
EP2728002B1 (en) 2011-06-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN110680920A (zh) 2011-09-30 2020-01-14 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
EP3778889A1 (en) * 2011-09-30 2021-02-17 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
SG11201405137QA (en) 2012-02-24 2014-12-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
AU2013268418B2 (en) 2012-05-30 2017-12-07 Chugai Seiyaku Kabushiki Kaisha Target-tissue-specific antigen-binding molecule
GB201211120D0 (en) 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2015083764A1 (ja) 2013-12-04 2015-06-11 中外製薬株式会社 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
ES2818800T3 (es) 2014-06-11 2021-04-14 Idac Theranostics Inc Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario
DK3326641T3 (da) 2015-04-22 2019-09-30 Curevac Ag Rna-holdig sammensætning til behandling af tumorsygdomme
EP3305322A4 (en) 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
EP3350202A1 (en) 2015-09-18 2018-07-25 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
CA3006743A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
SG10201707267RA (en) 2015-12-18 2017-10-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
AU2019318031A1 (en) 2018-08-10 2021-02-25 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
BR112022011723A2 (pt) 2019-12-27 2022-09-06 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4 e uso do mesmo
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
US20240002510A2 (en) 2021-06-25 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody and use thereof
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用

Also Published As

Publication number Publication date
CN105980557A (zh) 2016-09-28
CN111304752A (zh) 2020-06-19
AU2014358191B2 (en) 2020-12-24
TW201610247A (zh) 2016-03-16
JP7488843B2 (ja) 2024-05-22
US11912989B2 (en) 2024-02-27
JP7065150B2 (ja) 2022-05-11
AU2014358191A1 (en) 2016-06-02
CA2931296A1 (en) 2015-06-11
EP3763813A1 (en) 2021-01-13
US20240158785A1 (en) 2024-05-16
TW201937018A (zh) 2019-09-16
JP7060317B2 (ja) 2022-04-26
US10961530B2 (en) 2021-03-30
EP3078744A4 (en) 2017-06-07
EP3078744B1 (en) 2020-08-26
SG11201604495PA (en) 2016-07-28
KR20160093666A (ko) 2016-08-08
TWI702316B (zh) 2020-08-21
JPWO2015083764A1 (ja) 2017-03-16
KR102284503B1 (ko) 2021-07-30
EP3078744A1 (en) 2016-10-12
KR102454360B1 (ko) 2022-10-12
MX2016007312A (es) 2017-01-13
KR20210096309A (ko) 2021-08-04
JP2022115883A (ja) 2022-08-09
TW202043467A (zh) 2020-12-01
US20160304862A1 (en) 2016-10-20
KR20220142539A (ko) 2022-10-21
BR112016012094A2 (pt) 2017-09-26
TWI664331B (zh) 2019-07-01
AU2021201173A1 (en) 2021-03-11
US20210180049A1 (en) 2021-06-17
EA201691154A1 (ru) 2016-10-31
CA2931296C (en) 2024-04-23
JP2020146061A (ja) 2020-09-17
WO2015083764A1 (ja) 2015-06-11
CN105980557B (zh) 2020-04-07

Similar Documents

Publication Publication Date Title
DK3078744T3 (da) Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
DK3380522T3 (da) Antistofmolekyler til april og anvendelser deraf
DK3572527T3 (da) Fremgangsmåder og præparater til fremstilling af nukleinsyrebiblioteker
DK3406633T3 (da) Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
DK3218406T3 (da) Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
DK3356401T3 (da) Bindingsmolekyler med modificeret j-kæde
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3177643T3 (da) Bispecifikke T-celle-aktiverende antigenbindende molekyler
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
DK3192812T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2809795T3 (da) Materialer og fremgangsmåder til syntese af fejlminimerede nukleinsyremolekyler
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2968415T3 (da) Cd123-specifik kimær antigenreceptor-omdirigerede t-celler og fremgangsmåder til anvendelse deraf
DK2838917T3 (da) Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3138489T3 (da) Sæt til bestemmelse af en analytkoncentration
DK2989203T3 (da) Syntetisk bibliotek for specifikke bindingsmolekyler
DK3083680T3 (da) Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer